Johannes Henricus Matthias Schellens - 01 Aug 2024 Form 3 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role: Chief Medical Officer
Signature: /s/ Jan H.M. Schellens
Issuer symbol: LIXT
Transactions as of: 01 Aug 2024
Net transactions value: $0
Form type: 3
Filing time: 01 Aug 2024, 16:05:14 UTC
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LIXT	Options to Purchase Common Stock							01 Aug 2024	Common Stock	15,000	$2.39	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

Effective July 1, 2024, under his Consulting Agreement with the Company, the Reporting Person was granted five-year options to purchase an aggregate of 15,000 shares of the Company's Common Stock vesting quarterly over a three year period commencing on the last day of each calendar quarter commencing September 30, 2024 until fully vested. On August 1, 2024, pursuant to the Consulting Agreement, the Reporting Person was appointed as the Company's Chief Medical Officer.